Centhaquine

Centhaquine
Clinical data
Trade names	Lyfaquin
Other names	Centhaquin; PMZ-2010; Compound-7173
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 2-[2-[4-(3-Methylphenyl)piperazin-1-yl]ethyl]quinoline;
CAS Number	57961-90-7 ;
PubChem CID	162163 ;
DrugBank	DB16122 ;
ChemSpider	142413 ;
UNII	QD4VI0J9T5 ;
KEGG	D11974 ;
ChEMBL	ChEMBL4594437 ;
CompTox Dashboard (EPA)	DTXSID40206680 ;
Chemical and physical data
Formula	C22H25N3
Molar mass	331.463 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC1=CC(=CC=C1)N2CCN(CC2)CCC3=NC4=CC=CC=C4C=C3;
	InChI InChI=InChI=1S/C22H25N3/c1-18-5-4-7-21(17-18)25-15-13-24(14-16-25)12-11-20-10-9-19-6-2-3-8-22(19)23-20/h2-10,17H,11-16H2,1H3; Key:UJNWGFBJUHIJKK-UHFFFAOYSA-N;

Last updated November 30, 2025

Centhaquine (brand name Lyfaquin) is a cardiovascular drug.^[1] In India, it is approved for the treatment of hypovolemic shock.^[2]

Centhaquine is a vasopressor that activates α_2A- and α_2B-adrenoreceptors.^[3] It increases venous return and improves tissue perfusion. The drug has more recently been identified as a potent and selective serotonin 5-HT_2C receptor agonist (EC₅₀ Tooltip half-maximal effective concentration = 35 nM).^[4] It has no detectable activity at the serotonin 5-HT_2B or 5-HT_2C receptors.^[4]

References

↑ Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. (June 2021). "Resuscitative Effect of Centhaquine (Lyfaquin^®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial". Advances in Therapy. 38 (6): 3223–3265. doi:10.1007/s12325-021-01760-4. PMC 8189997 . PMID 33970455.
↑ "Marketing authorization received for Lyfaquin (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency" (Press release). May 14, 2020. Archived from the original on August 9, 2022. Retrieved April 25, 2024.
↑ Chalkias A, Pais G, Gulati A (March 2024). "Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species". International Journal of Molecular Sciences. 25 (6): 3494. doi: 10.3390/ijms25063494 . PMC 10970680 . PMID 38542464.
1 2 Adhikari AS, Yadav A, Pandit S, Kumar S, Pandey VK, Maurya AK, et al. (26 November 2025). "Synthesis and Evaluation of Novel Aza-Aromatics as Dual 5-HT2A and 5-HT2C Receptor Agonists". ACS Medicinal Chemistry Letters. doi:10.1021/acsmedchemlett.5c00505. ISSN 1948-5875 . Retrieved 29 November 2025.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. (June 2021). "Resuscitative Effect of Centhaquine (Lyfaquin^®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial". Advances in Therapy. 38 (6): 3223–3265. doi:10.1007/s12325-021-01760-4. PMC 8189997 . PMID 33970455.

[2] "Marketing authorization received for Lyfaquin (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency" (Press release). May 14, 2020. Archived from the original on August 9, 2022. Retrieved April 25, 2024.

[3] Chalkias A, Pais G, Gulati A (March 2024). "Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species". International Journal of Molecular Sciences. 25 (6): 3494. doi: 10.3390/ijms25063494 . PMC 10970680 . PMID 38542464.

[AdhikariYadavPandit2025-4] 1 2 Adhikari AS, Yadav A, Pandit S, Kumar S, Pandey VK, Maurya AK, et al. (26 November 2025). "Synthesis and Evaluation of Novel Aza-Aromatics as Dual 5-HT2A and 5-HT2C Receptor Agonists". ACS Medicinal Chemistry Letters. doi:10.1021/acsmedchemlett.5c00505. ISSN 1948-5875 . Retrieved 29 November 2025.

[1]

[2]

[3]

[4]